{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:14:07Z","timestamp":1772558047836,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-16063294"],"award-info":[{"award-number":["RS-2025-16063294"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-16071698"],"award-info":[{"award-number":["RS-2025-16071698"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-02413635"],"award-info":[{"award-number":["RS-2025-02413635"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["800-20240487"],"award-info":[{"award-number":["800-20240487"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128279","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:15:09Z","timestamp":1769714109000},"page":"128279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunological response of using emulsifying elongation factor 1 alpha of Plasmodium falciparum-based vaccines in complete Freund's adjuvant"],"prefix":"10.1016","volume":"75","author":[{"given":"Hyelee","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hui","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solchan","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seon-Ju","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128279_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00016-8","article-title":"The 2023 WHO world malaria report","volume":"5","author":"Venkatesan","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128279_bb0010","series-title":"The protozoan phylum Apicomplexa","author":"Levine","year":"1988"},{"key":"10.1016\/j.vaccine.2026.128279_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.587933","article-title":"Host-malaria parasite interactions and impacts on mutual evolution","volume":"10","author":"Su","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199172","article-title":"Seasonal variations in plasmodium falciparum parasite prevalence assessed by varying diagnostic tests in asymptomatic children in southern Ghana","volume":"13","author":"Ayanful-Torgby","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2026.128279_bb0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (Mosquirix): an overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128279_bb0030","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1080\/21645515.2019.1586040","article-title":"Safety profile of the RTS,S\/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa","volume":"15","author":"Guerra Mendoza","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128279_bb0035","series-title":"WHO recommends R21\/matrix-M vaccine for malaria prevention in updated advice on immunization","author":"Organization WH","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128279_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4269\/ajtmh.16-0141","article-title":"Global epidemiology of plasmodium vivax","volume":"95","author":"Howes","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2026.128279_bb0045","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-3024.2009.01138.x","article-title":"Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming \u2018vaccine resistant malaria\u2019","volume":"31","author":"Takala","year":"2009","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41541-018-0068-2","article-title":"A plasmodium berghei sporozoite-based vaccination platform against human malaria","volume":"3","author":"Mendes","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128279_bb0055","doi-asserted-by":"crossref","first-page":"17928","DOI":"10.1038\/s41598-021-96986-1","article-title":"A universal vaccine candidate against plasmodium vivax malaria confers protective immunity against the three PvCSP alleles","volume":"11","author":"Gimenez","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128279_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(98)00035-8","article-title":"Malaria parasites contain two identical copies of an elongation factor 1 alpha gene","volume":"94","author":"Vinkenoog","year":"1998","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.13021","article-title":"Histamine releasing factor and elongation factor 1 alpha secreted via malaria parasites extracellular vesicles promote immune evasion by inhibiting specific T cell responses","volume":"21","author":"Demarta-Gatsi","year":"2019","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/ilar.41.2.99","article-title":"Humane endpoints for infectious disease animal models","volume":"41","author":"Olfert","year":"2000","journal-title":"ILAR J"},{"key":"10.1016\/j.vaccine.2026.128279_bb0075","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1038\/s41598-024-72039-1","article-title":"Using weight loss to predict outcome and define a humane endpoint in preclinical sepsis studies","volume":"14","author":"Brochut","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128279_bb0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3347\/PHD.23093","article-title":"Evaluation of the antimalarial activity of SAM13-2HCl with morpholine amide (SKM13 derivative) against antimalarial drug-resistant plasmodium falciparum and plasmodium berghei infected ICR mice","volume":"62","author":"Hong","year":"2024","journal-title":"Parasites Hosts Dis"},{"key":"10.1016\/j.vaccine.2026.128279_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113194","article-title":"Optimisation and validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 spike, RBD, and nucleoprotein IgG, IgM, and IgA antibodies in Uganda","volume":"14","author":"Oluka","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0090","doi-asserted-by":"crossref","first-page":"W174","DOI":"10.1093\/nar\/gkv342","article-title":"I-TASSER server: new development for protein structure and function predictions","volume":"43","author":"Yang","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2026.128279_bb0095","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1146\/annurev.micro.55.1.673","article-title":"Antigenic variation at the infected red cell surface in malaria","volume":"55","author":"Kyes","year":"2001","journal-title":"Ann Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0100","doi-asserted-by":"crossref","DOI":"10.4081\/oncol.2012.e17","article-title":"Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection","volume":"6","author":"Senba","year":"2012","journal-title":"Oncol Rev"},{"key":"10.1016\/j.vaccine.2026.128279_bb0105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12866-015-0436-2","article-title":"Eukaryotic translation elongation factor-1 alpha is associated with a specific subset of mRNAs in Trypanosoma cruzi","volume":"15","author":"Alves","year":"2015","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2875-13-100","article-title":"A flow cytometric assay to quantify invasion of red blood cells by rodent plasmodium parasites in vivo","volume":"13","author":"Lelliott","year":"2014","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128279_bb0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/bs.mie.2019.05.020","article-title":"CFSE dilution to study human T and NK cell proliferation in vitro","volume":"631","author":"Terren","year":"2020","journal-title":"Methods Enzymol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128279_bib381","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41541-023-00714-x","article-title":"Protective antibody threshold of RTS,S\/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model","volume":"8","author":"Genito","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128279_bib382","doi-asserted-by":"crossref","first-page":"102298","DOI":"10.1016\/j.isci.2021.102298","article-title":"Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation","volume":"24","author":"Ganneru","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2026.128279_bb0120","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1046\/j.1523-1755.1999.00369.x","article-title":"Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis","volume":"55","author":"Holdsworth","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.vaccine.2026.128279_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2020.107944","article-title":"Measuring of IgG2c isotype instead of IgG2a in immunized C57BL\/6 mice with plasmodium vivax TRAP as a subunit vaccine candidate in order to correct interpretation of Th1 versus Th2 immune response","volume":"216","author":"Nazeri","year":"2020","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00323-20","article-title":"Murine cross-reactive nonneutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice","volume":"94","author":"Shibuya","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0135","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.4049\/jimmunol.178.4.2415","article-title":"TLR9 signaling in B cells determines class switch recombination to IgG2a","volume":"178","author":"Jegerlehner","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41541-023-00781-0","article-title":"Co-adjuvanting DDA\/TDB liposomes with a TLR7 agonist allows for IgG2a\/c class-switching in the absence of Th1 cells","volume":"8","author":"Zimmermann","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128279_bb0145","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1016\/S0264-410X(01)00145-1","article-title":"From genome to vaccine: in silico predictions, ex vivo verification","volume":"19","author":"De Groot","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128279_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127637","article-title":"Altered HLA class I profile associated with type a\/D Nucleophosmin mutation points to possible anti-Nucleophosmin immune response in acute myeloid Leukemia","volume":"10","author":"Kuzelova","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2026.128279_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/vaccines3020203","article-title":"Epitope prediction assays combined with validation assays strongly narrows down putative cytotoxic T lymphocyte epitopes","volume":"3","author":"Ip","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128279_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12859-023-05175-6","article-title":"Immunoinformatics-aided design of a new multi-epitope vaccine adjuvanted with domain 4 of pneumolysin against Streptococcus pneumoniae strains","volume":"24","author":"Shafaghi","year":"2023","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.vaccine.2026.128279_bb0165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12967-022-03590-6","article-title":"In silico designing of a novel epitope-based candidate vaccine against Streptococcus pneumoniae with introduction of a new domain of PepO as adjuvant","volume":"20","author":"Bahadori","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.vaccine.2026.128279_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110167","article-title":"HLA-A(*)02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses","volume":"37","author":"Nesterenko","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.128279_bb0175","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/eji.201343324","article-title":"Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation","volume":"43","author":"Rosalia","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0180","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1475-2875-9-76","article-title":"Solution structure of a plasmodium falciparum AMA-1\/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria","volume":"9","author":"Peng","year":"2010","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128279_bb0185","doi-asserted-by":"crossref","first-page":"388","DOI":"10.6026\/97320630013388","article-title":"Molecular docking based screening of a simulated HIF-1 protein model for potential inhibitors","volume":"13","author":"Latha","year":"2017","journal-title":"Bioinformation"},{"key":"10.1016\/j.vaccine.2026.128279_bb0190","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0161-5890(95)00043-E","article-title":"Relative implication of peptide residues in binding to major histocompatibility complex class I H-2Db: application to the design of high-affinity, allele-specific peptides","volume":"32","author":"Hudrisier","year":"1995","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0195","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1073\/pnas.1000032107","article-title":"Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition","volume":"107","author":"Theodossis","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.128279_bb0200","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1523-1747.2000.00084.x","article-title":"Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells","volume":"115","author":"Kukutsch","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0205","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1073\/pnas.0337629100","article-title":"The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria","volume":"100","author":"Makobongo","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.128279_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131456","article-title":"Analysis of a multi-component multi-stage malaria vaccine candidate--tackling the cocktail challenge","volume":"10","author":"Boes","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2026.128279_bb0215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12936-019-2826-7","article-title":"Clinical expression and antigenic profiles of a plasmodium vivax vaccine candidate: merozoite surface protein 7 (PvMSP-7)","volume":"18","author":"Cheng","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128279_bb0220","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijpara.2010.11.003","article-title":"Interaction of apicoplast-encoded elongation factor (EF) EF-Tu with nuclear-encoded EF-Ts mediates translation in the Plasmodiumfalciparum plastid","volume":"41","author":"Biswas","year":"2011","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0225","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.4049\/jimmunol.135.5.3498","article-title":"Production of IL 2 and IFN-gamma by T cells from malaria patients in response to plasmodium falciparum or erythrocyte antigens in vitro","volume":"135","author":"Troye-Blomberg","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0230","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.4049\/jimmunol.143.6.2038","article-title":"Role of IFN-gamma in lethal and nonlethal malaria in susceptible and resistant murine hosts","volume":"143","author":"Shear","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0235","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1016\/j.vaccine.2009.06.066","article-title":"Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells","volume":"27","author":"Huaman","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128279_bb0240","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.4049\/jimmunol.1101106","article-title":"Recombinant viral-vectored vaccines expressing plasmodium Chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection","volume":"188","author":"Biswas","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0245","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.4049\/jimmunol.150.5.2072","article-title":"Complete Freund\u2019s adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice","volume":"150","author":"Qin","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/eji.200737189","article-title":"Critical role for IFN-gamma in natural killer cell-mediated protection from diabetes","volume":"38","author":"Lee","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0255","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.22390","article-title":"Loss of tolerance in C57BL\/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease","volume":"48","author":"Wakabayashi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2026.128279_bb0260","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.4049\/jimmunol.1600155","article-title":"Discriminating protective from nonprotective plasmodium-specific CD8+ T cell responses","volume":"196","author":"Doll","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0265","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00165-21","article-title":"Plasmodium Preerythrocytic vaccine antigens enhance sterile protection in mice induced by Circumsporozoite protein","volume":"89","author":"Daniel","year":"2021","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128279_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127032","article-title":"Immunogenicity and efficacy in mice of two adjuvant formulations based on the C -and N-terminus of merozoite surface protein 1 of plasmodium yoelii","volume":"55","author":"Yun","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128279_bb0275","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4049\/jimmunol.1200688","article-title":"IFN-\u03b3-producing CD4 T cells promote experimental cerebral malaria by modulating CD8 T cell accumulation within the brain","volume":"189","author":"Villegas-Mendez","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0280","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1073\/pnas.87.14.5484","article-title":"Production by activated human T cells of interleukin 4 but not interferon-gamma is associated with elevated levels of serum antibodies to activating malaria antigens","volume":"87","author":"Troye-Blomberg","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.128279_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015948","article-title":"CD4+ T cells modulate expansion and survival but not functional properties of effector and memory CD8+ T cells induced by malaria sporozoites","volume":"6","author":"Overstreet","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2026.128279_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax4489","article-title":"IgM in human immunity to Plasmodium falciparum malaria","volume":"5","author":"Boyle","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2026.128279_bb0295","first-page":"122","article-title":"An evaluation of distress following intraperitoneal immunization with Freund\u2019s adjuvant in mice","volume":"39","author":"Toth","year":"1989","journal-title":"Lab Anim Sci"},{"key":"10.1016\/j.vaccine.2026.128279_bb0300","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.0105-2896.2004.00144.x","article-title":"Modulating vaccine responses with dendritic cells and toll-like receptors","volume":"199","author":"Pulendran","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2026.128279_bb0305","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1189\/jlb.70.6.849","article-title":"Modes of action of Freund\u2019s adjuvants in experimental models of autoimmune diseases","volume":"70","author":"Billiau","year":"2001","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0310","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1016\/j.vaccine.2019.04.092","article-title":"Keerti, Sahasrabuddhe AA, Dube a: visceral leishmaniasis: an overview of vaccine adjuvants and their applications","volume":"37","author":"Ratnapriya","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128279_bb0315","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1099\/jmm.0.040857-0","article-title":"ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases","volume":"61","author":"Baz Morelli","year":"2012","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0320","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.vaccine.2005.11.041","article-title":"Immunogenicity and protective efficacy of Escherichia coli expressed plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants","volume":"24","author":"Sachdeva","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128279_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.868305","article-title":"Immunization with CSP and a RIG-I agonist is effective in inducing a functional and protective humoral response against plasmodium","volume":"13","author":"Teixeira","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0330","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/intimm\/dxg049","article-title":"Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid","volume":"15","author":"Cribbs","year":"2003","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0335","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-022-00542-5","article-title":"Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant","volume":"7","author":"Yang","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128279_bb0340","first-page":"8","article-title":"Soares IS: a multistage formulation based on full-length CSP and AMA-1 ectodomain of plasmodium vivax induces high antibody Titers and T-cells and partially protects mice challenged with a transgenic plasmodium berghei parasite","author":"Lima","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2026.128279_bb0345","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1475-2875-12-136","article-title":"Mechanisms of protective immune responses induced by the plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine","volume":"12","author":"McCoy","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128279_bb0350","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00430-019-00606-9","article-title":"Immunological evaluation of two novel engineered plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL\/6 mice","volume":"208","author":"Shabani","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0355","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-025-01089-x","article-title":"iDC-targeting PfCSP mRNA vaccine confers superior protection against plasmodium compared to conventional mRNA","volume":"10","author":"Yanik","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128279_bb0360","doi-asserted-by":"crossref","first-page":"300","DOI":"10.62940\/als.v8i3.1183","article-title":"Reconnoitering lipoproteins to design subunit vaccine by immunoinformatics approach","volume":"8","author":"Naeem","year":"2021","journal-title":"Adv Life Sci"},{"key":"10.1016\/j.vaccine.2026.128279_bb0365","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btad780","article-title":"MHCSeqNet2-improved peptide-class I MHC binding prediction for alleles with low data","volume":"40","author":"Wongklaew","year":"2024","journal-title":"Bioinformatics"},{"key":"10.1016\/j.vaccine.2026.128279_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1116868","article-title":"3D interaction homology: the hydrophobic residues alanine, isoleucine, leucine, proline and valine play different structural roles in soluble and membrane proteins","volume":"10","author":"Al Mughram","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.vaccine.2026.128279_bb0375","first-page":"217","article-title":"A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics","volume":"12","author":"Bogdanos","year":"2005","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.vaccine.2026.128279_bb0380","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1080\/21645515.2016.1171439","article-title":"Mechanistic insights into influenza vaccine-associated narcolepsy","volume":"12","author":"Ahmed","year":"2016","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:48:52Z","timestamp":1772552932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":78,"alternative-id":["S0264410X26000873"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128279","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological response of using emulsifying elongation factor 1 alpha of Plasmodium falciparum-based vaccines in complete Freund's adjuvant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128279"}}